South Korea BCG Vaccine Market

South Korea BCG Vaccine Market Insights Forecasts to 2035

• The South Korea BCG Vaccine Market Size is Expected to Grow at a CAGR of around 5.5% from 2025 to 2035
• The South Korea BCG Vaccine Market Size is Expected to hold a significant Share by 2035

According to a research report published by Dicision Advisosrs& Consulting, The South Korea BCG Vaccine Market Size is anticipated to grow at a CAGR of 5.5% from 2025 to 2035. The market is driven by ongoing prevalence of tuberculosis (TB), continued use of BCG in neonatal immunization programs, and its expanding role in bladder cancer immunotherapy. Government vaccination mandates, improving healthcare access, and rising R&D into novel BCG formulations are also supporting market growth.

Market Overview

The South Korea BCG vaccine market consists of the healthcare industry segment involved in production, distribution, and administration of the Bacillus Calmette–Guérin (BCG) vaccine, most specifically for prevention of tuberculosis (TB) and for some therapeutic approaches for bladder cancer. The market will continue to grow because South Korea has prioritized TB control even if the number of cases in the country has generally been declining. Vaccination and the importance of vaccination programs have been heightened in South Korea, and there is significant interest from the government and public health agencies in TB control through vaccination and as part of immunization programs offering the BCG vaccination. Continuous research on BCG and its therapeutic potential and formulations will create future opportunity. Existing conditions such as fluctuations in vaccine supply and other advanced TB preventive measures may restrict expansion of the market alternatively.

Report Coverage

This research report categorizes the market for the South Korea BCG vaccine market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea BCG vaccine market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea BCG vaccine market.

Driving Factors

The South Korea BCG vaccine market is driven by government immunization initiatives and the high coverage achieved through the national schedule, combined with the continued burden of tuberculosis, which means preventive programs are required. The public health consciousness, increasing research interest in BCG use outside of TB, and ongoing foreign collaborations for the development and supply of vaccines help to maintain high prospects for growth in the market.

Restraining Factors

The South Korea BCG vaccine market is restrained by the ever-changing global supply, manufacturing difficulties, and a reliance on limited producers. Further, declining TB incidence, growing competition by new TB preventing approaches, and concerns regarding variable efficacy of the vaccine in adults limits market growth in the BCG vaccination market.

Market Segmentation

The South Korea BCG vaccine market share is classified into product type and application.

• The immune BCG segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea BCG vaccine market is segmented by product type into immune BCG and therapy BCG. Among these, the immune BCG segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This segment has a large share of the market as BCG is a required childhood vaccine under South Korea’s national immunization schedule, resulting in high coverage and continuous demand for tuberculosis prevention.

• The tuberculosis segment dominated the market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea BCG vaccine market is segmented by application into tuberculosis, bladder cancer, and others. Among these, the tuberculosis segment dominated the market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the government led vaccinatoin campaigns given that South Korea has a persistent TB burden, which has made its use compulsory for newborns.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea BCG vaccine market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Dicision Advisosrs has segmented the South Korea BCG vaccine market based on the below-mentioned segments:

South Korea BCG Vaccine Market, By Product Type

• Immune BCG
• Therapy BCG

South Korea BCG Vaccine Market, Application

• Tuberculosis
• Bladder Cancer
• Others